Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well...

|By:, SA News Editor

Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well tolerated when used in conjunction with Roche's Avastin in a Phase II trial, with no additional safety concerns. Oxigene expects patient accrual for the study to be completed within the next 3-4 months and for top-line data to be available at the end of the year. (PR)